NewsBenzingaCellectar Biosciences Reports Results From Case Study Highlighting Durable Complete Response In Heavily Pretreated Patient With Diffuse Large B-Cell Lymphoma Treated With Iopofosine I 131 Cellectar Biosciences Reports Results From Case Study Highlighting Durable Complete Response In Heavily Pretreated Patient With Diffuse Large B-Cell Lymphoma Treated With Iopofosine I 131 Benzinga 2026.10.27 11:16 (GMT+0) Open on Benzinga Other news Morgan Stanley Maintains Equal-Weight on W.W. Grainger, Raises Price Target to $1590 SpaceX's IPO Playbook Could Give Anthropic A $19B Buying Cushion—But There's A Catch What Is Going on With CoreWeave Stock on Monday? Morgan Stanley Maintains Underweight on Virgin Galactic Holdings, Lowers Price Target to $1.75 Occidental Petroleum Analyst Turns Bearish Due To Limited Volume Upside If You Invested $1000 In Monster Beverage Stock 5 Years Ago, You Would Have This Much Today